Aarti Pharmalabs achieves SBTi approval of GHG emission reduction targets
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
The company has paid an Interim Environmental Damage Compensation of Rs. 3.40 lakh to GPCB
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
Subscribe To Our Newsletter & Stay Updated